Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results

TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-November 5, 2026 — Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first half fiscal 2027 ended September 30, 2026.

“We were pleased with our second quarter and first half revenue and EPS performance, driven by continued strength in our leading brands and strong early contributions from the Breathe Right® portfolio and LaCorium acquisitions that closed in June and July, respectively. Our portfolio performed in line with our expectations, with strong consumption growth across channels including eCommerce. This translated into strong mid-single-digit earnings growth and sets us up for continued strong free cash flow moving forward,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.

Second Fiscal Quarter Ended September 30, 2026

Reported revenues in the second quarter of fiscal 2027 of $336.3 million increased 22.7% from $274.1 million in the second quarter of fiscal 2026, but decreased 1.6% excluding the impacts of foreign currency and a $65.1 million contribution from the acquisition of the Breathe Right® portfolio and LaCorium. The organic revenue performance versus the prior year comparable period reflected the expected headwind associated with order timing in Q1 and a decline in Clear Eyes®.

Reported net income for the second quarter of fiscal 2027 totaled $25.3 million, or $0.53 in diluted earnings per share, compared to $42.2 million, or $0.86 in diluted earnings per share, for the comparable period of fiscal 2026. On an adjusted non-GAAP basis, second quarter fiscal 2027 net income totaled $53.8 million, or $1.13 in diluted earnings per share, versus $52.5 million in net income and $1.07 in diluted earnings per share in the prior year comparable period.

Adjustments to net income in the second quarter of fiscal 2027 included certain costs associated with acquisitions including integration, transition, purchase accounting, legal and various other costs, such as costs associated with improving and optimizing the acquired Pillar5 facility for increases in long-term capacity, a loss on extinguishment of debt, associated tax adjustments and a normalized tax adjustment pertaining to the establishment of a valuation allowance against deferred tax assets. The adjustment to the second quarter of fiscal 2026 relates to a discrete tax item pertaining to establishing a taxable presence in a new state.

Six Months Ended September 30, 2026

Reported revenues for the first six months of fiscal 2027 totaled $602.0 million and compared to revenues of $523.6 million for the first six months of fiscal 2026. Revenues increased 15.0% versus the prior year comparable period and 0.7% excluding the impact of foreign currency and a $71.0 million contribution from the acquisition of the Breathe Right® portfolio and LaCorium. The organic revenue

increase for the first six months reflected increased demand across the broad portfolio which more than offset a decline in Clear Eyes®.

Reported net income for the first six months of fiscal 2027 totaled $54.5 million versus the prior year comparable period net income of $89.7 million. Non-GAAP adjusted net income for the first six months of fiscal 2027 totaled $100.3 million versus the prior year comparable period’s adjusted net income of $99.9 million. Diluted earnings per share were $1.14 for the first six months of fiscal 2027 compared to $1.81 per share in the prior year comparable period. Non-GAAP adjusted diluted earnings per share of $2.11 for the first six months of fiscal 2027 increased over the prior year comparable period’s adjusted diluted earnings per share of $2.02.

Adjustments to net income in the first six months of fiscal 2027 included certain costs associated with acquisitions including integration, transition, purchase accounting, legal and various other costs, such as costs associated with improving and optimizing the acquired Pillar5 facility for increases in long-term capacity, as well as a loss on extinguishment of debt, associated tax adjustments, and a normalized tax adjustment pertaining to the establishment of a valuation allowance against deferred tax assets. The adjustment to the first six months of fiscal 2026 relates to a discrete tax item pertaining to establishing a taxable presence in a new state.

Free Cash Flow and Balance Sheet

The Company's net cash provided by operating activities for the first six months of fiscal 2027 was $108.7 million, compared to $136.5 million during the prior year comparable period. Non-GAAP adjusted free cash flow in the first six months of fiscal 2027 was $123.0 million compared to $133.6 million in the prior year comparable period.

The Company's net debt position as of September 30, 2026 was approximately $2 billion. On July 15, 2026, the Company issued $400 million of new 6.25% senior notes due July 2034, which replaced the same principal of senior notes previously due in fiscal 2028.

Segment Review

North American OTC Healthcare: Segment revenues of $271.8 million for the second quarter fiscal 2027 increased 17.8% compared to the prior year comparable quarter's segment revenues of $230.8 million. The revenue increase was driven by a $47.5 million contribution from the acquisitions of the Breathe Right® portfolio and LaCorium, partially offset by lower base business sales associated with accelerated order timing in first quarter fiscal 2027.

For the first six months of the current fiscal year, reported revenues for the North American OTC segment were $498.0 million, which compared to $443.3 million in the prior year comparable period.

The revenue increase was primarily driven by a $52.0 million contribution from the acquisitions of the Breathe Right® portfolio and LaCorium, as well as higher CompoundW® and TheraTears® sales.

International OTC Healthcare: Fiscal second quarter 2027 segment revenues of $64.5 million increased 48.7% compared to $43.4 million reported in the prior year comparable period. The revenue performance was primarily driven by a $17.6 million contribution from the acquisitions of the Breathe Right® portfolio and LaCorium, as well as double-digit sales growth for Hydralyte®.

For the first six months of the current fiscal year, reported revenues for the International OTC Healthcare segment were $104.0 million, an increase of approximately 30% over the prior year comparable period’s revenues of $80.3 million. Strong revenue growth was primarily driven by a $19.0

million contribution from the acquisitions of the Breathe Right® portfolio and LaCorium, as well as continued growth for Hydralyte®.

Updated Fiscal 2027 Outlook

Ron Lombardi, Chief Executive Officer, stated, "We are updating our fiscal 2027 outlook for revenues to $1,280 million to $1,290 million and adjusted diluted EPS of $4.48 to $4.55 primarily to reflect recent variability in Clear Eyes® production at Pillar5, which is expected to reduce product availability and revenue in the second half. While supply remains limited for Clear Eyes®, we continue to invest in our Pillar5 production site with the intent of delivering consistent quality output that generates long-term growth for the brand."

"It's important to note that our outlook for the remainder of the portfolio is unchanged, with the base business delivering growth and our recent acquisitions on track to deliver sales and profit consistent with our prior guidance. Against a challenging consumer environment, this is a testament to our trusted brands and diversified business model."

			Previous Fiscal 2027 Outlook			Current Fiscal 2027 Outlook
Revenue			$1,290 to $1,315 million			$1,280 to $1,290 million
Organic Revenue Growth			+1.0% to +3.0%			~ Flat
Adjusted Diluted E.P.S.			$4.55 to $4.65			$4.48 to $4.55
Adjusted Free Cash Flow			$270 million or more			$265 million or more

Second Quarter Fiscal 2027 Conference Call, Accompanying Slide Presentation and Replay

The Company will host a conference call to review its second quarter and first half fiscal 2027 results today, November 5, 2026 at 8:30 a.m. ET. The Company provides a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at http://www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start. The slide presentation can be accessed from the Investor Relations page of the Company’s website by clicking on Webcasts and Presentations.

A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.

Non-GAAP and Other Financial Information

In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.

Note Regarding Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "guidance," "outlook," "may," "will," "would," “believe,” “set up,” "expect," “on track,” "anticipate,” “positioned,” or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding the Company's future operating results including revenues, organic growth, adjusted diluted earnings per share, and adjusted free cash flow; supply of Clear Eyes® and return to category leadership; the expected impact of Breathe Right® and LaCorium Health acquisitions on the Company’s sales and profit; the Company’s ability to rapidly reduce debt; and the Company’s ability to manage through the current environment through its business strategy and diverse product portfolio. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact of business and economic conditions, including as a result of evolving U.S. and international tariffs, labor shortages, inflation and geopolitical instability, consumer trends, the impact of the Company’s advertising and marketing and new product development initiatives, customer inventory management initiatives and ordering patterns, fluctuating foreign exchange rates, competitive pressures, and the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption as a result of labor shortages. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic reports filed with the Securities and Exchange Commission.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading consumer healthcare company growing trusted, category-defining brands. Headquartered in New York, the Company markets, sells, manufactures and distributes its products across the U.S., Canada, Australia, and select other international markets. Its diverse portfolio of iconic brands includes Breathe Right®, Monistat®, Summer's Eve®, BC®, Goody's®, Dramamine®, Fleet®, Hydralyte®, Gaviscon®, DenTek®, TheraTears®, Clear Eyes®, Compound W®, Dermal Therapy®, Chloraseptic®, Luden's®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, and Debrox®, among others. Learn more at www.prestigeconsumerhealthcare.com.

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Income and Comprehensive Income

(Unaudited)

						Three Months Ended September 30,												Six Months Ended September 30,
(In thousands, except per share data)						2026						2025						2026						2025
Total Revenues						$	336,307					$	274,114					$	602,017					$	523,644
Cost of Sales
Cost of sales excluding depreciation						160,512						120,043						286,978						226,758
Cost of sales depreciation						3,257						2,492						6,313						4,976
Cost of sales						163,769						122,535						293,291						231,734
Gross profit						172,538						151,579						308,726						291,910
Operating Expenses
Advertising and marketing						52,226						38,701						86,894						73,638
General and administrative						30,893						28,037						74,196						56,493
Depreciation and amortization						8,707						5,171						14,404						10,353
Total operating expenses						91,826						71,909						175,494						140,484
Operating income						80,712						79,670						133,232						151,426
Other expense
Interest expense, net						30,026						10,036						43,971						20,239
Loss on extinguishment of debt						1,360						—						1,360						—
Other expense, net						1,876						501						1,910						277
Total other expense, net						33,262						10,537						47,241						20,516
Income before income taxes						47,450						69,133						85,991						130,910
Provision for income taxes						22,155						26,922						31,519						41,233
Net income						$	25,295					$	42,211					$	54,472					$	89,677
Earnings per share:
Basic						$	0.53					$	0.86					$	1.15					$	1.82
Diluted						$	0.53					$	0.86					$	1.14					$	1.81
Weighted average shares outstanding:
Basic						47,495						49,025						47,479						49,249
Diluted						47,593						49,264						47,599						49,547
Comprehensive income, net of tax:
Currency translation adjustments						1,352						655						42						6,059
Total other comprehensive income						1,352						655						42						6,059
Comprehensive income						$	26,647					$	42,866					$	54,514					$	95,736

Prestige Consumer Healthcare Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)			September 30, 2026						March 31, 2026
Assets
Current assets
Cash and cash equivalents			$	46,515					$	63,868
Accounts receivable, net of allowance of $24,135 and $18,187, respectively			244,124						191,920
Inventories			179,203						159,132
Prepaid expenses and other current assets			22,286						16,564
Total current assets			492,128						431,484
Property, plant and equipment, net			116,868						121,689
Operating lease right-of-use assets			24,621						27,780
Finance lease right-of-use assets, net			20,136						21,776
Goodwill			705,264						581,109
Intangible assets, net			3,357,059						2,299,605
Other long-term assets			5,585						10,870
Total Assets			$	4,721,661					$	3,494,313
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable			$	44,020					$	22,791
Accrued interest payable			16,528						15,578
Operating lease liabilities, current portion			7,218						6,910
Finance lease liabilities, current portion			2,743						2,656
Other accrued liabilities			97,994						72,989
Total current liabilities			168,503						120,924
Long-term debt, net			2,079,324						993,953
Deferred income tax liabilities			489,533						447,417
Long-term operating lease liabilities, net of current portion			17,509						20,955
Long-term finance lease liabilities, net of current portion			16,576						17,968
Other long-term liabilities			5,551						5,580
Total Liabilities			2,776,996						1,606,797
Total Stockholders' Equity			1,944,665						1,887,516
Total Liabilities and Stockholders' Equity			$	4,721,661					$	3,494,313

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Cash Flows

			Six Months Ended September 30,
(In thousands)			2026						2025
Operating Activities
Net income			$	54,472					$	89,677
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			20,717						15,329
Loss on disposal of property and equipment			333						131
Deferred and other income taxes			15,460						23,211
Amortization of debt origination costs			2,109						889
Amortization of acquired inventory step-up			17,207						—
Stock-based compensation costs			5,225						5,449
Loss on extinguishment of debt			1,360						—
Non-cash operating lease cost			4,192						3,879
Changes in operating assets and liabilities, net of the effects of acquisitions:
Accounts receivable			(45,392)						(2,580)
Inventories			3,566						(10,277)
Prepaid expenses and other current assets			(6,181)						(11,767)
Accounts payable			16,023						22,545
Accrued liabilities			24,003						3,923
Operating lease liabilities			(4,185)						(3,839)
Other			(256)						(71)
Net cash provided by operating activities			108,653						136,499
Investing Activities
Purchases of property, plant and equipment			(7,327)						(2,940)
Acquisitions, net of cash acquired			(1,193,557)						—
Other			(1,757)						(1,927)
Net cash (used in) investing activities			(1,202,641)						(4,867)
Financing Activities
Proceeds from issuance of Term Loan			1,140,000						—
Net increase in line of credit			887						—
Term loan repayments			(30,000)						—
Proceeds from issuance of senior notes			400,000						—
Repayment of senior notes			(400,000)						—
Payments of debt issuance costs			(28,829)						—
Payments of finance leases			(1,231)						(1,147)
Proceeds from exercise of stock options			94						3,907
Fair value of shares surrendered as payment of tax withholding			(2,684)						(4,216)
Repurchase of common stock			—						(109,775)
Other			(1,486)						—
Net cash provided by (used in) financing activities			1,076,751						(111,231)
Effects of exchange rate changes on cash and cash equivalents			(116)						821
(Decrease) increase in cash and cash equivalents			(17,353)						21,222
Cash and cash equivalents - beginning of period			63,868						97,884
Cash and cash equivalents - end of period			$	46,515					$	119,106
Interest paid			$	41,124					$	21,879
Income taxes paid			$	24,027					$	25,088

Prestige Consumer Healthcare Inc.

Condensed Consolidated Statements of Income

Business Segments

(Unaudited)

			Three Months Ended September 30, 2026
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	271,812					$	64,495											$	336,307
Cost of sales			132,992						30,777												163,769
Gross profit			138,820						33,718												172,538
Advertising and marketing			40,488						11,738												52,226
Contribution margin			$	98,332					$	21,980											$	120,312
Other operating expenses																					39,600
Operating income																					$	80,712

*Intersegment revenues of $0.9 million were eliminated from the North American OTC Healthcare segment.

			Six Months Ended September 30, 2026
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	498,018					$	103,999											$	602,017
Cost of sales			243,257						50,034												293,291
Gross profit			254,761						53,965												308,726
Advertising and marketing			69,418						17,476												86,894
Contribution margin			$	185,343					$	36,489											$	221,832
Other operating expenses																					88,600
Operating income																					$	133,232

			Three Months Ended September 30, 2025
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	230,756					$	43,358											$	274,114
Cost of sales			102,348						20,187												122,535
Gross profit			128,408						23,171												151,579
Advertising and marketing			32,033						6,668												38,701
Contribution margin			$	96,375					$	16,503											$	112,878
Other operating expenses																					33,208
Operating income																					$	79,670

*Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment.

			Six Months Ended September 30, 2025
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	443,334					$	80,310											$	523,644
Cost of sales			194,526						37,208												231,734
Gross profit			248,808						43,102												291,910
Advertising and marketing			60,987						12,651												73,638
Contribution margin			$	187,821					$	30,451											$	218,272
Other operating expenses																					66,846
Operating income																					$	151,426

* Intersegment revenues of $1.2 million were eliminated from the North American OTC Healthcare segment.